Regulatory Considerations for Impurity Qualification: ICH Q3A/Q3C/Q3D, RLD & MDD
23:56
Administrative Aspects of Managing a Drug Master File (DMF)
21:51
Safety Evaluation of Drug Substance Impurities in Generics
29:42
CMC Considerations for CAR T Cell Product Development
35:21
Decrease RTR, IR, and CR Due to Dissolution Deficiencies (21of28) GDF – Apr. 3-4, 2019
25:35
Application of (Q)SAR and Expert Knowledge for ICH M7 Impurity Classification
21:57
Biopharmaceutics Risk Assessment to Guide Dissolution Method Development for Solid Oral Dosage Forms
8:05:29
December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)
24:20